Posted inOncology Specialties Urology
Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis
This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.